

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

Current Report  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): December 14, 2015		
<b>LEXARIA CORP.</b> (Exact name of registrant as specified in its charter)		
Nevada (State or other jurisdiction of incorporation)	000-52138 (Commission File Number)	20-2000871 (IRS Employer Identification No.)
#950 – 1130 West Pender Street, Vancouver, British Columbia, Canada V6E 4A4		
Registrant's telephone number, including area code: (604) 602-1675		
(Former name or former address, if changed since last report.)		

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))
-

**Item 1.01 Entry into a Material Definitive Agreement Item 3.02 Unregistered Sales of Equity Securities**

On December 14, 2015, Lexaria signed an Investor Relations contract with Radius Consulting Inc. for a 45 day term. Radius will receive \$2,500 and 50,000 common shares at a price of \$0.20 per share.

The Company issued the units to one (1) US persons pursuant to the exemption from registration provided for under Rule 506 of Regulation D, promulgated under the United States Securities Act 1933, as amended. Each of the subscribers represented that they were an “accredited investor” as such term is defined in Regulation D

The securities referred to herein will not be and have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

**Item 7.01 Regulation FD Disclosure.**

A copy of the news release announcing the private placement is filed as exhibit 99.1 to this current report and is hereby incorporated by reference.

**TEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.**

<a href="#"><u>10.1</u></a>	<a href="#"><u>Radius Consulting Inc. contract signed on December 14, 2015</u></a>
<a href="#"><u>99.1</u></a>	<a href="#"><u>Press Release dated December 14, 2015</u></a>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 14, 2015

Lexaria Corp.

(Signature) By: *"/s/ Chris Bunka"*  
Chris Bunka  
CEO

---

---

# RADIUS

## CONSULTING AGREEMENT

This Agreement ("Agreement") is entered into between RADIUS Consulting, Inc. ("Consultant") and Lexaria Corp. ("Company") effective this day December 9<sup>th</sup>, 2015 (the "Effective Date").

In consideration of the mutual promise contained herein and on the terms and conditions hereinafter set forth, the Company and Consultant (together, the "Parties") agree as follows:

### 1. PROVISION OF SERVICES

Consultant shall, on a non-exclusive basis, to the extent reasonably required in the conduct of the business of the Company, place at the disposal of the Company, its judgment and experience, and, to such extent and at the written request of the Company, provide business development and financial marketing services, and various investor and public relations services on behalf of the Company including without limitation the following:

- A) Facilitate introductions to the professional investment community to include but not be limited to, prospective registered representatives, securities analysts and institutional investors via road show events, telephone calls, and other electronic communications.
- B) Coordinate and execute ongoing communication to include, but not be limited by, distribution of each financial and general press release to Consultant's relevant databases and related investor networks as each becomes publicly available.
- C) Provide general IR advisory services to include but not be limited to, press release editorial services, online monitoring, best practice guidance, and shareholder communications.

The services described in paragraphs A through C are referred to collectively as, the "Services."

Consultant shall use its best effort in the furnishing of the Services, and for this purpose shall, at times, maintain or keep and make available qualified persons or a network of qualified outside professionals (the "Affiliates") for the performance of the Services under this Agreement at no additional cost to the Company. To the extent reasonably practical, Consultant shall use its own personnel rather than outside professionals in the performance of the Services hereunder.

Notwithstanding anything to the contrary herein, the Parties agree that any and promotional and marketing campaigns and materials, marketing summaries and teasers and other materials of the Company used in the performance of the Services ("Marketing Materials") shall be reviewed by the Company and approved in writing by the Company. All costs associated with dissemination of the Marketing Materials will be paid by Consultant.

### 2. COMPENSATION & TERM

For a term ("Term") of forty-five (45) days the Company shall pay to Consultant for its services \$2,500 upon closing and 50,000 restricted shares for services rendered.

### 3. OTHER AGREEMENTS, REPRESENTATIONS, WARRANTIES AND COVENANTS

The Company acknowledges and agrees that the Consultant carries neither professional licenses nor memberships in any self-regulatory organizations.

It is further acknowledged and agreed by the Company that the Consultant is not rendering legal advice or performing accounting services and is not acting and shall not act as an investment advisor or broker dealer within the meaning of any applicable state or federal securities laws.

The Consultant represents, warrants and covenants that its activities during the Term and subsequent to the Term will comply in all respects with the federal and state securities laws including without limitation Sections 5(a), 5(c) and 17(a) of the Securities Act of 1933 ("Securities Act"), Sections 10(b) and 13(d) of the Securities Exchange Act of 1934 ("Exchange Act"), and Rules 10b-5, 13d-1 and 13d-2 thereunder. The Consultant will refrain from any activities which, directly or indirectly, could be deemed manipulation of the Company's securities including without limitation wash sales, matched orders, manipulative trading, or false or misleading press releases. Consultant further agrees, either directly or indirectly, not to engage in any short sales of the Company's securities during the Term hereof and for a ninety (90) day period following the expiration of this Agreement. Further, Consultant will not provide a sell recommendation to anyone regarding Company stock, or at any time advise anyone to sell the Company's stock.

The Consultant agrees and covenants that during the Term it will only transmit, distribute, or otherwise disseminate the Company's filings, press releases, and other presentations of factual nature endorsed in writing by the Company in its efforts to promote market awareness of the Company, and in accordance with the conditions of Section 1 of the Agreement.

#### **4. CONFIDENTIALITY**

Consultant acknowledges that it will have access to confidential information regarding the Company and its business. Consultant agrees that it will not, during or subsequent to the Term of this Agreement, except in performance of the Services, use, divulge, furnish or make accessible to any person (other than with the written permission of the Company) any knowledge or information or plans of the Company with respect to the Company or its business, including, but not by way of limitation, the products and trade secrets of the Company, whether in the concept or development stage, or being marketed by the Company. Upon the termination of the Agreement, and at the written request of the Company, the Consultant will return all confidential materials to the Company without retaining duplicates or copies.

#### **4. INDEPENDENT CONTRACTOR STATUS**

The Consultant agrees to perform its consulting duties hereto as an independent contractor. Nothing contained herein shall be considered to create an employer- employee relationship between the parties to this Agreement. The Company shall not make social security, workers' compensation or unemployment insurance payments on behalf of Consultant. The Parties hereto acknowledge and agree that the Consultant cannot guarantee the results or effectiveness of any of the Services rendered by the Consultant. Rather, Consultant shall conduct its operations and provide the Services in a professional manner and in accordance with good industry practice. The Consultant will use its reasonable business efforts in providing Services to the Company.

#### **5. OTHER ACTIVITIES OF CONSULTANT**

The Company recognizes that Consultant now renders and may continue to render management and other services to other companies which may or may not have policies and conduct activities similar to those of the Company. Consultant shall be free to render such advice and other services and the Company hereby consents hereto. Consultant shall not be required to devote its full time and attention to the performance of its duties under this Agreement, but shall devote the resources it deems reasonable or necessary for such purposes.

#### **6. INDEMNIFICATION**

The Consultant agrees to indemnify and hold harmless the Company and its respective officers, agents, directors, employees, and attorneys against any losses, claims, damages or liabilities, joint or several, to which either party, or any such other person, may become subject, insofar as such losses, claims, damages or liabilities (or actions, suits or proceedings in respect thereof) arise out of or are arising from

RADIUS

the Consultant's or its Affiliates' activities on behalf of the Company hereunder, and due to the Consultant's negligence or wrongdoing, and will reimburse the Company, or any such other person, for any legal or other expenses reasonably incurred by the Company, or any such other person, in connection with investigation or defending any such loss, claim, damage, liability, or action, suit or proceeding.

**7. IN GENERAL**

This Agreement sets forth the entire Agreement, and the understanding between the parties with respect to its subject matter and supersedes all prior discussions, agreements and understandings, of every and any nature between them with respect thereto. This Agreement shall be governed by and construed in accordance with the laws of the state of Texas applicable to agreements made to be performed entirely within such state.


In witness whereof, the parties have caused this Agreement to be signed by their respective officers or representatives duly authorized on the day and year first above written.

"Consultant"  
RADIUS Consulting Inc.

\_\_\_\_\_  
Justin Kulik  
Partner

"Company"  
Lexaria Corp.

X

  
\_\_\_\_\_  
Chris Brunke, CEO  
Print Name & Title

---

## Lexaria Enters Investors Relations Contract with RADIUS

KELOWNA, BC-- December 14, 2015 - Lexaria Corp. (OTCQB: LXP) (CNSX: LXX) (the "Company" or "Lexaria") has signed an Investor Relations and media coverage services agreement with RADIUS Consulting, initially on a 45-day trial basis, to provide services. RADIUS is a well known, New York-based firm that has provided services to Nasdaq-listed and other firms.

RADIUS is a full-service investor relations firm leveraging 15 years experience providing strategic awareness across all investor mediums from road show events to daily outreach targeting institutional, retail, and media networks. RADIUS specializes in positioning small cap issuers for uplist to a senior exchange across a diverse range of sectors including technology, healthcare/life sciences, digital media, consumer/internet retail, natural resources and financial services. For more information visit <http://www.RadiusIR.com>

Lexaria expects to receive media expertise as RADIUS will leverage its full-spectrum media database comprised of print, television, and online opinion leaders. Ongoing communication will be conducted as material events are disseminated by the Company, since RADIUS clients are routinely featured by major media outlets. RADIUS will also provide targeted daily retail and institutional outreach and leverage its diverse finance providers, M&A partners and knowledge of the uplisting process to ensure Lexaria is properly positioned for long-term growth.

Lexaria is paying US\$2,500 and issuing 50,000 restricted common shares are being awarded as payment for the services. Services are to begin immediately.

Justin Kulik, Managing Partner of RADIUS, commented, "In evaluating early stage life science issuers with potential to achieve meaningful long-term growth, we look for innovative technology, proven management and ripe well-defined markets. Following our review and discussions with Lexaria management we believe the Company is trending accordingly to build solid market share in the New Year. We are excited to work closely with management on all aspects of corporate communications and investor relations as the Company continues to execute its growth strategy."

### About Lexaria

Lexaria is a food sciences company, with common shares quoted in the USA with symbol LXP and in Canada with symbol LXX. The Company uses innovative technology to deliver unique food experiences. [www.lexarienergy.com](http://www.lexarienergy.com)

### About ViPova™

ViPova™ uses only legal CBD oil extracts, grown from agricultural hemp in locations where it is legal to do so, in ViPova™-branded tea. ViPova™ uses its patent-pending process to infuse concentrated amounts of CBD within lipids in its tea, providing more bioactivity and comfort to the body during the absorption process. Only ViPova™ has this ground-breaking technology for CBD/lipid infusion. [www.vipova.com](http://www.vipova.com)

---

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.  
Chris Bunka  
Chairman & CEO  
(250) 765-6424

#### **FORWARD-LOOKING STATEMENTS**

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements, including but not limited to: the provision of any significant investor relations or media relations services. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, the patent application and approval process and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the medical marijuana, hemp oil sector, or alternative health businesses will provide any benefit to Lexaria, or that the Company will experience any growth through participation in these sectors. There is no assurance that existing capital is sufficient for the Company's needs or that it will not need to attempt to raise additional capital. There is no assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any hemp oil or cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever. There is no assurance that the cannabinoid/lipid infusion technology will provide any increase in bioavailability to any individual person. There is no assurance that any patent application in the USA or any other nation or under any treaty will result in the award of an actual patent; nor that an award of any actual patent will protect against challenges from unknown third parties. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). ViPova™ products and Lexaria Energy products are not intended to diagnose, treat, cure or prevent any disease.

*The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.*

---